SciSparc Ltd.SPRC
Market cap
P/E ratio
| Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Revenues | - | - | - | - | - | 1 | 3 | 1 |
| Cost of goods sold | - | - | - | - | - | 0 | 1 | 1 |
| Gross profit | - | - | - | - | - | 1 | 2 | 1 |
| Research and development expenses | -2 | 3 | 2 | 1 | 2 | 3 | 2 | 2 |
| Sales and marketing | - | - | - | - | - | - | 1 | 2 |
| Impairment of intangible assets | - | - | - | - | - | - | - | 1 |
| General and administrative expenses | -4 | 7 | 2 | 2 | 4 | 7 | 5 | 5 |
| Other income | - | - | - | - | - | - | - | 1 |
| Operating loss | 6 | -10 | -4 | -3 | -6 | -8 | -7 | -7 |
| Equity losses from the investment in MitoCareX | - | - | - | - | - | -0 | -0 | -0 |
| Finance income | -0 | 1 | 0 | 1 | - | 8 | 2 | 1 |
| Finance expenses | -0 | 0 | 1 | 1 | 0 | 2 | 1 | 0 |
| Loss before income taxes | 6 | -9 | - | - | - | -3 | -6 | -7 |
| Taxes on income | - | -0 | - | - | - | 0 | 0 | -0 |
| Total comprehensive loss | 6 | 9 | 5 | 4 | -6 | -3 | -6 | -7 |
| Equity holders of the Company | 6 | 9 | - | - | 6 | 3 | -5 | -6 |
| Non-controlling interests | - | 0 | -0 | 0 | - | - | -1 | -1 |
| Total comprehensive loss | 6 | 9 | 5 | 4 | -6 | -3 | -6 | -7 |
| Basic loss per ordinary share attributable to equity holders of the Company: (in Dollars per share) | - | - | - | 0.1 | 2.83 | - | 14.43 | 1.28 |
| Diluted loss per ordinary share attributable to equity holders of the Company: (in Dollars per share) | - | - | - | 0.11 | - | - | 14.43 | 1.28 |